Maravai LifeSciences Holdings, Inc.
MRVI
$1.77
$0.052.91%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -23.92% | -2.49% | 6.51% | -18.79% | -63.78% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -23.92% | -2.49% | 6.51% | -18.79% | -63.78% |
| Cost of Revenue | 6.65% | 0.38% | -11.56% | 13.83% | -34.07% |
| Gross Profit | -51.42% | -5.98% | 37.00% | -43.01% | -74.23% |
| SG&A Expenses | 19.97% | 0.57% | 14.64% | 5.73% | 2.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.38% | 0.45% | 1.53% | 10.14% | -25.00% |
| Operating Income | -44,103.28% | -15.54% | 23.11% | -892.46% | -99.94% |
| Income Before Tax | -107.09% | -754.17% | -26.66% | -395.45% | 584.41% |
| Income Tax Expenses | -100.00% | 105.69% | -71.36% | 108.54% | 8,970.30% |
| Earnings from Continuing Operations | 57.72% | -1,065.11% | -21.34% | -1,582.49% | -225.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 405.84% | 790.24% | 27.86% | 727.63% | 108.08% |
| Net Income | 75.33% | -1,432.62% | -15.96% | -17,926.87% | -381.55% |
| EBIT | -44,103.28% | -15.54% | 23.11% | -892.46% | -99.94% |
| EBITDA | -233.25% | -49.31% | 140.21% | -173.98% | -90.48% |
| EPS Basic | 77.00% | -1,327.76% | -12.50% | -18,160.00% | -380.48% |
| Normalized Basic EPS | -99.93% | 2,275.24% | 2.40% | -168.38% | 5,068.35% |
| EPS Diluted | 77.00% | -1,300.00% | -12.50% | -18,160.00% | -380.48% |
| Normalized Diluted EPS | -99.93% | 2,275.24% | 2.40% | -168.38% | 5,068.35% |
| Average Basic Shares Outstanding | 7.32% | 7.30% | 3.02% | 0.45% | 0.39% |
| Average Diluted Shares Outstanding | 7.32% | 7.30% | 3.02% | 0.45% | 0.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |